Blood Science (Jul 2023)

Exosome miRNAs profiling in serum and prognostic evaluation in patients with multiple myeloma

  • Teng Fang,
  • Hao Sun,
  • Xiyue Sun,
  • Yi He,
  • Peixia Tang,
  • Lixin Gong,
  • Zhen Yu,
  • Lanting Liu,
  • Shiyi Xie,
  • Tingyu Wang,
  • Zhenshu Xu,
  • Shuhua Yi,
  • Gang An,
  • Yan Xu,
  • Guoqing Zhu,
  • Lugui Qiu,
  • Mu Hao

DOI
https://doi.org/10.1097/BS9.0000000000000160
Journal volume & issue
Vol. 5, no. 3
pp. 196 – 208

Abstract

Read online

MicroRNAs (MiRNAs) carried by exosomes play pivotal roles in the crosstalk between cell components in the tumor microenvironment. Our study aimed at identifying the expression profile of exosomal miRNAs (exo-miRNAs) in the serum of multiple myeloma (MM) patients and investigating the regulation networks and their potential functions by integrated bioinformatics analysis. Exosomes in serum from 19 newly diagnosed MM patients and 9 healthy donors were isolated and the miRNA profile was investigated by small RNA sequencing. Differential expression of exo-miRNAs was calculated and target genes of miRNAs were predicted. CytoHubba was applied to identify the hub miRNAs and core target genes. The LASSO Cox regression model was used to develop the prognostic model, and the ESTIMATE immune score was calculated to investigate the correlation between the model and immune status in MM patients. The top six hub differentially expressed serum exo-miRNAs were identified. 513 target genes of the six hub exo-miRNAs were confirmed to be differentially expressed in MM cells in the Zhan Myeloma microarray dataset. Functional enrichment analysis indicated that these target genes were mainly involved in mRNA splicing, cellular response to stress, and deubiquitination. 13 core exo-miRNA target genes were applied to create a novel prognostic signature to provide risk stratification for MM patients, which is associated with the immune microenvironment of MM patients. Our study comprehensively investigated the exo-miRNA profiles in MM patients. A novel prognostic signature was constructed to facilitate the risk stratification of MM patients with distinct outcomes.